Felbamato come terapia aggiuntiva nelle epilessie parziali farmacorsistenti dell'adulto

Translated title of the contribution: Felbamate as add-on therapy in adult patients with partial drug- resistant epilepsy

S. Binelli, L. Canafoglia, D. Mamoli, G. Avanzini, L. Guidolin, R. Canger, L. Politini, I. Sartori, A. Tartara, E. Perucca, S. Giubergia, P. Mazzari, P. Zagnoni, P. Garofalo, C. Durisotti, S. Ricci, M. Manfredi, F. Mainardi, F. Paladin, R. MichelucciC. A. Tassinari, E. Sasso, D. Mancia, G. Zaccara, V. Mascia, F. Marrosu, C. Nocerino, S. Striano, A. Spinelli, L. M. Specchio, M. Russo, A. Alagna, F. Pisani, R. Di Perri, G. Raspanti, O. Daniele, B. Bettini, A. Zibetti, R. Montanini, G. Lunardi

Research output: Contribution to journalArticlepeer-review

Abstract

The study was aimed to evaluate the efficacy and the tolerability of Felbamate (FLB) in adult patients with refractory partial epilepsy. Felbamate was given as add-on therapy, according to a multicenter; randomized, double- blind, placebo-controlled trial. Felbamate resulted significantly more effective than Placebo in reducing the percentage of seizures; in 38% of patients treated with FLB a reduction of seizures greater than 50% was obtained and 11% of them resulted seizure-free. Adverse experiences with FLB were considered generally mild or moderate.

Translated title of the contributionFelbamate as add-on therapy in adult patients with partial drug- resistant epilepsy
Original languageItalian
Pages (from-to)317-318
Number of pages2
JournalBollettino - Lega Italiana contro l'Epilessia
Issue number106-107
Publication statusPublished - 1999

ASJC Scopus subject areas

  • Clinical Neurology

Fingerprint Dive into the research topics of 'Felbamate as add-on therapy in adult patients with partial drug- resistant epilepsy'. Together they form a unique fingerprint.

Cite this